Operation of the percutaneous endoscopic gastrostomy-jejunostomy tube without endoscopy in patients with Parkinson’s disease on levodopa-carbidopa intestinal gel infusion therapy
Introduction: Tube-related adverse events (AEs) occur frequently in patients with Parkinson’s disease (PD) receiving levodopa-carbidopa intestinal gel therapy. Endoscopy has become evasive since the beginning of the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to evaluate methods t...
Main Authors: | Yohei Mukai, Hiroyuki Toyoda, Kenji Miyama, Yuji Takahashi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-01-01
|
Series: | Clinical Parkinsonism & Related Disorders |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590112520300475 |
Similar Items
-
Complications of percutaneous endoscopic gastrostomy-jejunostomy for levodopa/carbidopa infusion in advanced Parkinson's disease
by: Ana Olivares, et al.
Published: (2012-03-01) -
Ascorbic acid can alleviate the degradation of levodopa and carbidopa induced by magnesium oxide
by: Noriyuki Miyaue, et al.
Published: (2022-07-01) -
The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program
by: Peter A. LeWitt, et al.
Published: (2022-11-01) -
Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
by: Mezin Öthman, et al.
Published: (2021-03-01) -
Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced Parkinson’s Disease
by: Michael J. Soileau, et al.
Published: (2023-01-01)